Avotermin

Summary

Avotermin (CHEMBL2108833) is a phase-3 clinical-stage protein; indicated across 3 conditions including keloid and severe cutaneous adverse reaction.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 3 conditions
• Clinical trials: 20

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108833
Name	Avotermin
Type	Protein
Max phase	3

Also known as: Avotermin, Avotermina, Avotermine, Human tgfb3, Juvista, AVOTERMIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
keloid	1	MONDO:0005348	EFO:0004212
severe cutaneous adverse reaction	1	MONDO:0005594	EFO:0006346

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE2	8
PHASE1/PHASE2	8
PHASE1	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00742443	PHASE3	COMPLETED	Juvista in Scar Revision Surgery of Disfiguring Scars
NCT00430326	PHASE2	COMPLETED	Juvista (Avotermin) in Scars Following Varicose Vein Removal
NCT00432211	PHASE2	UNKNOWN	Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.
NCT00432328	PHASE2	TERMINATED	Juvista (Avotermin) in Breast Reduction Surgery Scars
NCT00436449	PHASE2	COMPLETED	RN1001(Avotermin) in Scar Improvement Following Breast Augmentation
NCT00469235	PHASE1/PHASE2	COMPLETED	Trial of Juvista (Avotermin) Following Removal of Ear Lobe Keloid Scars
NCT00627536	PHASE2	COMPLETED	Scar-Improvement Efficacy and Safety of a Single Intradermal Injection of Avotermin (Juvista) Administered Following Full-Thickness Skin Incisions
NCT00629811	PHASE2	COMPLETED	Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and Women
NCT00656227	PHASE2	UNKNOWN	A Trial to Investigate Scar Improvement Efficacy of RN1001 (Avotermin) After Head and Neck Naevi Excision
NCT00710333	PHASE1/PHASE2	COMPLETED	Safety of Juvista When Administered Following Excision of Ear Lobe Keloids
NCT00836147	PHASE1/PHASE2	COMPLETED	Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe Keloids
NCT00847795	PHASE1/PHASE2	COMPLETED	Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.
NCT00847925	PHASE1/PHASE2	COMPLETED	Safety and Efficacy of RN1001(Avotermin) in Healthy Male Subjects
NCT00977951	PHASE1/PHASE2	COMPLETED	Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male Subjects
NCT00978367	PHASE1/PHASE2	COMPLETED	Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)
NCT00984503	PHASE2	COMPLETED	Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor Sites
NCT00984581	PHASE1/PHASE2	COMPLETED	Safety and Efficacy Study of Avotermin (Juvista) in Female Subjects
NCT00978302	PHASE1	COMPLETED	Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)
NCT01029158	PHASE1	COMPLETED	A Trial to Compare the Efficacy of Two Formulations of Avotermin Against Placebo
NCT00821457	Not specified	WITHDRAWN	Juvista in the Non-surgical Improvement of Existing Scars

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).